China Pricing and Reimbursement Market-System overview
Download the report to find out about the Chinese pharmaceutical pricing & reimbursement process, including, Payer Evaluation, Price setting, Reimbursement and Cost containment.
Brazil Pricing and Reimbursement Market-System overview
Download the report to find out about the Brazilian pharmaceutical pricing & reimbursement process, including, Payer Evaluation, Price setting, Reimbursement and Cost containment.
Case Study: Development of a Global Affordability Navigator to assess affordability solution strategies for a novel treatment in ulcerative colitis (UC)
Our client was launching a novel therapy for the treatment of Ulcerative Colitis (UC) and wanted to assess the strategic potential of patient affordability solutions across 13 international markets
Case Study: Consumer willingness to pay assessment for an HPV vaccine
The client had developed and launched a human papillomavirus (HPV) vaccine which was reimbursed for adolescents through national immunization programs for only some markets
Case Study: Identification and design of affordability solutions for an innovative treatment for sickle cell disease
The client developed an innovative treatment for sickle cell disease (SCD) and wanted to assess the payer and self-pay landscape, understand barriers to funding / purchase decisions, and identify affordability solutions to support access to Product X across markets in-scope
Case Study: Indication expansion assessment and evidence requirements for a novel agent in alpha-thalassemia
The client was preparing for an indication expansion of Product X, which was already indicated in other blood conditions, into alpha-thalassemia, an inherited blood disorder
Regulatory vs. Payer and Employer Expectations in Chronic Weight Management in the US
The FDA issued guidance for new products in chronic weight management setting a threshold for their efficacy to be at least a 5% mean change from baseline in body weight vs. placebo at 1 year.
Windrose Consulting group appoints three new Partners
Windrose Consulting Group is excited to announce the promotion of three outstanding team members to Partner level.
France Pricing and Reimbursement Market-System overview
Download the report to find out about the French pharmaceutical pricing & reimbursement process, including, Payer Evaluation, Price setting, Reimbursement and Cost containment.
New Starters in the UK, January 2025
Windrose Consulting Group are pleased to welcome the latest members of our team into the London office
US Pricing and Reimbursement Market-System overview
Download the report to find out how pricing and reimbursement decisions are made in the US, including, Payer Evaluation, Price setting and reimbursement
Italy Pricing and Reimbursement Market-System overview
Download the report to find out how pricing and reimbursement decisions are made in Italy, including, Payer Evaluation, Price setting and reimbursement
New Starters in the UK
Windrose Consulting Group are pleased to welcome the latest members of our team into the UK office; Inés Dieringer and Joana Guedes.
UK Pricing and Reimbursement Market-System overview
Download the report to find out how pricing and reimbursement decisions are made in the UK, including, Payer Evaluation, Price setting and reimbursement
Promotions at Windrose, October 2024
Windrose are delighted to announce twelve promotions in our team.
New Starters in the UK, September 2024
Windrose Consulting Group are pleased to welcome the latest members of our team into the UK office; Jenny Marsh, Aashray Gupta, Jason King and Mar Casajuana.
New Starters in the US, September 2024
Windrose Consulting Group are delighted to welcome the latest members of our team into the US office; Ari Levin, Katharine K Yang, Jack Minigutti, Simon Rickman, Michelle Wang, Jasmine Line and Daniel Shapiro.
Q&As with our 2024 Summer interns at Windrose
In this Q&A, we are featuring our 2024 Summer Interns; Amol and Ushaan
Will SUSTAIN-HTA bring clarity to the pan-EU JCA methodologies and priorities?
With less than a year to go until the launch of the Joint Clinical Assessment (JCA) in January 2025, its successful implementation relies on the readiness of each EU market and their willingness to incorporate the JCA into current HTA processes.
CMS’s Cell and Gene Therapy (CGT) Access Model: Implications of Outcome-based Payment Models for Pharmaceuticals
The recent FDA approval of two groundbreaking gene therapies for sickle cell disease —Casgevy and Lyfgenia—marks a significant milestone in the field, offering life-changing treatments for patients suffering from this debilitating genetic disorder.

